Navigation Links
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Date:5/12/2008

can identify which patients may benefit from 400IU of natural vitamin E. Administration of this dose and type of vitamin E led to a 50% reduction in non-fatal myocardial infarction in the ICARE study, reported earlier this year. The test is being developed to be used on current ubiquitous laboratory platforms (e.g., ELISA), and also to be used in genetic testing labs. The test is also being developed such that it will apply to CMS parameters for reimbursement. Once available, the Company plans to distribute the test to hospitals and other independent labs that have high volume customers.

To bring the most effective therapy to patients who will benefit most, Synvista has developed an extensive intellectual property portfolio based on utilizing haptoglobin genotyping or phenotyping to target the use of drugs in diabetic individuals with the Hp 2-2 genotype, thereby creating an unique product portfolio that both identifies a specific patient profile and provides therapeutic solutions to address patients' needs.

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing marke
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
2. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to be Featured on Wallst.net
5. Synvista Therapeutics to Present at the BIO InvestorForum 2007
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
9. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
10. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
11. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Albany, NewYork (PRWEB) September 01, 2014 ... Pharma, Biotech and Diagnostics report provides comprehensive understanding ... and agreements entered into by the worlds leading ... detailed understand and analysis of how and why ... flexibility of a prospective partner’s negotiated deals terms ...
(Date:8/31/2014)... 31, 2014 2014 Market ... a professional and in-depth research report on ... Polyacrylamide information, including Polyacrylamide definition, classification, application, ... industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Researcher Provides Extensive Experience In Molecular DiagnosticsSALT LAKE ... company revolutionizing spine care through the development of ... Macina, Ph.D., has joined the executive management team ... and Development. Dr. Macina will report directly to ...
... Feb. 24 Innovative Biosensors, Inc., and ProGenTech ... diagnostics, today announced an agreement to jointly develop ... incorporate Innovative Biosensor,s proprietary Cellular Analysis and Notification ... cell-based approach for quickly detecting various pathogens, into ...
... the gene that ultimately controls the production of tooth ... to the repair of damaged enamel, a new concept ... of replacement teeth. , The gene, called Ctip2, is ... several functions - in immune response, and the development ...
Cached Biology Technology:Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System 2Innovative Biosensors and ProGenTech Partner to Develop a Rapid Diagnostics System 3Genetic discovery could lead to advances in dental treatment 2
(Date:9/2/2014)... September 2, 2014 A study published in ... of the American Academy of Child and Adolescent ... with a psychiatric diagnosis had an increased risk ... antipsychotics. , Using data from the nationwide Danish ... Ren Ernst Nielsen, Psychiatry, Aalborg University Hospital, Denmark, ...
(Date:9/2/2014)... of lithographic limestone is well known as a ... that area (for example, Archaeopteryx). Now, for the ... the French equivalent of these outcrops - discoveries ... known water treader. , Despite the abundance of ... have been obtained from the Late Kimmeridgian equivalents ...
(Date:9/1/2014)... in the U.S. has improved steadily in recent yearsspurred ... dietary quality remains poor and disparities continue to widen ... study from Harvard School of Public Health (HSPH). , ... that the extensive efforts by many groups and individuals ... but it also indicates that these efforts need to ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... in German . It,s a quick process, ... seconds, a laser beam has welded the casing and speedometer cover ... is a perfect weld seam scarcely visible to the naked eye. ... welding. What,s more: the resulting heat is confined to a minimal ...
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... of Zaragoza (UNIZAR) has studied precipitation trends in Spain,s ... The results show that precipitation has declined overall between ... of the rainy season. The rains are heavier in ... ,Since 1946, the average precipitation falling on Spanish hydrological ...
Cached Biology News:Laser welding in the right light 2Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Rain in Spain is on the decline 2
... designed to rapidly and reliably amplify unknown ... Technology. APAgene provides hassle-free, ready-to use components, ... ingredients are provided in each kit. The ... gap filling, localized cloning of genomic DNA, ...
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
Biology Products: